Pulmonx Corporation Secures $60 Million Credit Facility with Perceptive Advisors to Strengthen Capital Structure and Support Growth Initiatives

Pulmonx Corporation secures a $60 million credit facility to enhance operations and promote its emphysema treatments.

Quiver AI Summary

Pulmonx Corporation has secured a five-year credit facility worth up to $60 million from Perceptive Advisors, which includes an initial $40 million term loan to refinance existing debt and the option for an additional $20 million subject to certain revenue milestones. This facility features interest-only payments until maturity in 2031 at a rate linked to one-month Term SOFR, with a 3.75% floor plus 7.0%. CEO Glen French stated that this new financing strengthens the company's capital structure and allows them to focus on their commercial and clinical strategies, particularly for their Zephyr Valve, a key treatment for severe emphysema. Perceptive Advisors expressed confidence in Pulmonx's management and its potential for sustainable growth. Further details can be found in the company's Form 8-K filed with the SEC.

Potential Positives

Pulmonx secured a five-year credit facility of up to $60 million, providing significant financial flexibility and capital to support its growth initiatives.
The new debt facility extends the debt maturity to 2031 with favorable terms, allowing the company to focus on executing its commercial strategy and advancing key clinical programs.
The facility includes an initial $40 million term loan to refinance existing debt, enhancing the company's capital structure and potentially improving financial stability.
The support from Perceptive Advisors reflects confidence in Pulmonx's management and its market-leading product, the Zephyr Valve, which addresses a significant unmet need for severe emphysema patients.

Potential Negatives

The credit facility involves refinancing existing debt, indicating potential prior financial distress or issues with cash flow management.
The interest rate of the loan, being substantially high (totaling a minimum of 10.75%), could place a financial burden on the company, especially if revenue targets are not met.
The necessity to achieve specific revenue milestones to access additional funding raises concerns about the company's current financial health and ability to grow sustainably.

FAQ

What is the recent financial announcement from Pulmonx Corporation?

Pulmonx announced a $60 million credit facility with Perceptive Advisors to refinance debt and support growth initiatives.

How will the new credit facility impact Pulmonx's operations?

The facility strengthens Pulmonx's capital structure, allowing the company to focus on its commercial strategy and clinical programs.

What are the terms of the credit facility?

The credit facility includes a $40 million term loan and an option for an additional $20 million, with favorable interest rates.

What does the Pulmonx Zephyr Valve offer to patients?

The Zephyr Valve is a minimally invasive treatment for severe emphysema, offering significant improvement in breathing and quality of life.

Where can more information about Pulmonx be found?

More information is available on Pulmonx's website at www.pulmonx.com and in their Form 8-K filed with the SEC.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$LUNG Insider Trading Activity

$LUNG insiders have traded $LUNG stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.

Here’s a breakdown of recent trading of $LUNG stock by insiders over the last 6 months:

DANIEL P FLORIN sold 23,321 shares for an estimated $46,408
DAVID AARON LEHMAN (GENERAL COUNSEL) has made 0 purchases and 4 sales selling 10,278 shares for an estimated $16,136.
GLENDON E. III FRENCH (President and CEO) has made 0 purchases and 2 sales selling 8,805 shares for an estimated $13,823.
GEOFFREY BERAN ROSE (CHIEF COMMERCIAL OFFICER) has made 0 purchases and 4 sales selling 6,322 shares for an estimated $9,925.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$LUNG Revenue

$LUNG had revenues of $21.5M in Q3 2025. This is an increase of 5.47% from the same period in the prior year.

You can track LUNG financials on Quiver Quantitative's LUNG stock page.

$LUNG Hedge Fund Activity

We have seen 48 institutional investors add shares of $LUNG stock to their portfolio, and 78 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

FMR LLC removed 2,099,156 shares (-96.5%) from their portfolio in Q4 2025, for an estimated $4,639,134
SOLEUS CAPITAL MANAGEMENT, L.P. added 2,038,323 shares (+inf%) to their portfolio in Q4 2025, for an estimated $4,504,693
EXODUSPOINT CAPITAL MANAGEMENT, LP added 1,951,173 shares (+inf%) to their portfolio in Q4 2025, for an estimated $4,312,092
DEERFIELD MANAGEMENT COMPANY, L.P. removed 1,890,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $3,061,800
BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. removed 1,168,513 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,892,991
KENT LAKE PR LLC added 926,157 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,500,374
VESTAL POINT CAPITAL, LP removed 830,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $1,834,300

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$LUNG Analyst Ratings

Wall Street analysts have issued reports on $LUNG in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

D. Boral Capital issued a "Buy" rating on 11/13/2025

To track analyst ratings and price targets for $LUNG, check out Quiver Quantitative's $LUNG forecast page.

$LUNG Price Targets

Multiple analysts have issued price targets for $LUNG recently. We have seen 2 analysts offer price targets for $LUNG in the last 6 months, with a median target of $9.0.

Here are some recent targets:

Jason Kolbert from D. Boral Capital set a target price of $14.0 on 02/20/2026
Frank Takkinen from Lake Street set a target price of $4.0 on 10/28/2025

Full Release

REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced the closing of a five-year credit facility for up to $60 million with Perceptive Advisors.

The credit facility consists of an initial $40 million term loan drawn at closing to refinance the Company’s existing debt, and an option to draw an additional $20 million in unfunded capital through the end of 2027, subject to the achievement of certain revenue milestones. The new facility is interest only until maturity in 2031, and bears interest at a rate equal to one-month Term SOFR (subject to a 3.75% floor) plus 7.0%, 2.0% of which may be “paid-in-kind” at the Company’s option for a period of three years following the closing date.

“This new debt facility immediately strengthens our capital structure,” said Glen French, President and Chief Executive Officer of Pulmonx. “By extending our debt maturity to 2031 with favorable terms, we can shift our focus toward executing our commercial strategy and advancing our key clinical programs to deliver our life-changing treatment to patients with severe emphysema.”

“The Pulmonx Zephyr Valve is a market-leading product backed by robust clinical evidence, global guideline endorsement, and broad reimbursement that fulfills a significant unmet need for severe emphysema patients who often have no other treatment options,” said Sam Chawla, Portfolio Manager at Perceptive Advisors. “This financing reflects our confidence in management’s ability to reposition the company for profitable and sustainable growth.”

Further details regarding the new credit agreement are included in the Company’s Form 8-K filed with the U.S. Securities and Exchange Commission on March 4, 2026.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect our strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. These forward-looking statements include, but are not limited to, statements about the Company’s expectations regarding the credit facility, including its impact on the Company’s business and financial position, and the Company’s ability to execute its commercial strategy and advance its key clinical programs. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Pulmonx’s public filings with the Securities and Exchange Commission (“SEC”), including our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025, filed with the SEC on November 12, 2025, available at www.sec.gov. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical fact are forward-looking statements. Except to the extent required by law, we undertake no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr ^® Endobronchial Valve, Chartis ^® Pulmonary Assessment System, LungTraX ^TM Platform, and StratX ^® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.pulmonx.com .

Pulmonx ^® , Chartis ^® , StratX ^® , and Zephyr ^® are registered trademarks and LungTraX ^TM is a trademark of Pulmonx Corporation.

About Perceptive Advisors
Founded in 1999, Perceptive Advisors focuses on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare. Today, the firm manages approximately $8 billion across its strategies. For more information about Perceptive, visit www.perceptivelife.com.

Investor Contact
Brian Johnston
Laine Morgan
Gilmartin Group
[email protected]